Jefferies Group’s Arcturus Therapeutics ARCT Stock Holding History

Jefferies Group’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,000	Closed	-$304K	–	1610
2020 Q4	$304K	Buy	+7,000	New	+$474K	﹤0.01%	1276

Other funds holding ARCT

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Group's ARCT Position: Q1 2021 in Review

Jefferies Group sold out of Arcturus Therapeutics (ARCT) in Q1 2021, closing a stake of 3,076 shares — an estimated $133K sold.

Jefferies Group first reported a position in ARCT in Q3 2014 and held it in 6 quarters. The position peaked at $536K in Q3 2020. 162 funds tracked by Wall St. Rank hold ARCT as of Q1 2021.

Jefferies Group reported no remaining Arcturus Therapeutics position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 3,076 Arcturus Therapeutics shares in Q1 2021, an estimated $133K.
Jefferies Group first reported a position in Arcturus Therapeutics in Q3 2014 and held it in 6 quarters.
Jefferies Group's Arcturus Therapeutics position peaked at $536K in Q3 2020.
162 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.